Table 4.
Patients’ histopathological characteristics and microsatellite instability (MSI) status, according to fulfillment (BGRev+) or nonfulfillment (BGRev-) of at least one criterion of the revised Bethesda guidelines
| Variable | BGRev- (n = 105) | BGRev+ (n = 45) | All patients | P | Odds ratio (95% confidence interval) |
|---|---|---|---|---|---|
|
Tumor infiltrating lymphocytes: |
0.130* |
||||
| 1 (present) |
38 |
18 |
56 |
||
| 2 (absent) |
67 |
27 |
94 |
||
|
Differentiation: |
0.632* |
||||
| 1 (undifferentiated and poorly differentiated) |
11 |
4 |
15 |
||
| 2 (moderately differentiated) |
45 |
20 |
65 |
||
| 3 (well differentiated) |
49 |
21 |
70 |
||
|
Mucin production: |
0.023* |
3.1 (4.1-4.4)† |
|||
| present |
77 |
21 |
98 |
||
| absent |
28 |
24 |
52 |
||
|
MSI status: |
0.0001* | 7 (2.5-19.9)† | |||
| High frequency of microsatellite instability |
4 |
15 |
19 |
||
| Microsatellite stable/low frequency of microsatellite instability | 101 | 30 | 131 |
*χ2 test.
†Mantel-Haenszel test.